Measles vector as a multigene delivery platform facilitating iPSC reprogramming.


Journal

Gene therapy
ISSN: 1476-5462
Titre abrégé: Gene Ther
Pays: England
ID NLM: 9421525

Informations de publication

Date de publication:
05 2019
Historique:
received: 26 09 2018
accepted: 09 01 2019
revised: 07 12 2018
pubmed: 6 2 2019
medline: 19 12 2019
entrez: 6 2 2019
Statut: ppublish

Résumé

Induced pluripotent stem cells (iPSCs) provide a unique platform for individualized cell therapy approaches. Currently, episomal DNA, mRNA, and Sendai virus-based RNA reprogramming systems are widely used to generate iPSCs. However, they all rely on the use of multiple (three to six) components (vectors/plasmids/mRNAs) leading to the production of partially reprogrammed cells, reducing the efficiency of the systems. We produced a one-cycle measles virus (MV) vector by substituting the viral attachment protein gene with the green fluorescent protein (GFP) gene. Here, we present a highly efficient multi-transgene delivery system based on a vaccine strain of MV, a non-integrating RNA virus that has a long-standing safety record in humans. Introduction of the four reprogramming factors OCT4, SOX2, KLF4, and cMYC via a single, "one-cycle" MV vector efficiently reprogrammed human somatic cells into iPSCs, whereas MV vector genomes are rapidly eliminated in derived iPSCs. Our MV vector system offers a new reprogramming platform for genomic modification-free iPSCs amenable for clinical translation.

Identifiants

pubmed: 30718755
doi: 10.1038/s41434-019-0058-7
pii: 10.1038/s41434-019-0058-7
pmc: PMC8228481
mid: NIHMS1708522
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

151-164

Subventions

Organisme : NIAID NIH HHS
ID : R21 AI114833
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI105233
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA015083
Pays : United States
Organisme : U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
ID : R21AI105233
Pays : International
Organisme : NCATS NIH HHS
ID : UL1 TR002377
Pays : United States
Organisme : U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (NCATS)
ID : UL1TR002377
Pays : International
Organisme : NCATS NIH HHS
ID : UL1 TR000135
Pays : United States

Références

Cell. 2006 Aug 25;126(4):663-76
pubmed: 16904174
J Virol. 1999 Nov;73(11):9568-75
pubmed: 10516065
Curr Top Microbiol Immunol. 2009;329:129-62
pubmed: 19198565
Nat Rev Drug Discov. 2017 Feb;16(2):115-130
pubmed: 27980341
Nature. 2011 Mar 3;471(7336):46-7
pubmed: 21368819
Proc Jpn Acad Ser B Phys Biol Sci. 2009;85(8):348-62
pubmed: 19838014
Stem Cells Transl Med. 2016 May;5(5):694-702
pubmed: 26987352
J Gene Med. 2003 Jul;5(7):543-53
pubmed: 12825193
Science. 2009 May 8;324(5928):797-801
pubmed: 19325077
PLoS One. 2014 Dec 05;9(12):e113052
pubmed: 25479600
Regen Med. 2016 Jan;11(1):105-32
pubmed: 26679838
Nat Rev Drug Discov. 2015 Oct;14(10):681-92
pubmed: 26391880
J Virol. 2001 Jan;75(2):910-20
pubmed: 11134304
EMBO J. 1987 Mar;6(3):681-8
pubmed: 3582370
J Virol. 2007 Oct;81(19):10597-605
pubmed: 17634218
J Infect Dis. 2003 May 15;187 Suppl 1:S291-8
pubmed: 12721928
Nat Biotechnol. 2015 Jan;33(1):58-63
pubmed: 25437882
Mol Ther Methods Clin Dev. 2016 Aug 24;3:16057
pubmed: 27606350
Expert Opin Biol Ther. 2017 Mar;17(3):353-363
pubmed: 28129716
Nat Methods. 2009 Nov;6(11):805-8
pubmed: 19838168
N Engl J Med. 2017 Mar 16;376(11):1038-1046
pubmed: 28296613
J Virol. 2000 Jul;74(14):6564-9
pubmed: 10864670
J Virol. 2009 Jan;83(2):961-8
pubmed: 19004947
J Virol. 2001 Jan;75(2):921-33
pubmed: 11134305
Nat Rev Mol Cell Biol. 2016 Mar;17(3):194-200
pubmed: 26908143
Cell Stem Cell. 2010 Nov 5;7(5):618-30
pubmed: 20888316
Science. 2017 Mar 17;355(6330):1109-1110
pubmed: 28302802
Cell. 2007 Nov 30;131(5):861-72
pubmed: 18035408
J Virol. 2006 May;80(9):4242-8
pubmed: 16611883
Mol Ther. 2013 Jan;21(1):228-39
pubmed: 23183535
Nat Methods. 2011 May;8(5):409-12
pubmed: 21460823
Stem Cells Transl Med. 2012 Jun;1(6):451-61
pubmed: 23197849
Virology. 2007 Mar 30;360(1):72-83
pubmed: 17112561
Nat Biotechnol. 2015 Sep;33(9):890-1
pubmed: 26348942
Proc Natl Acad Sci U S A. 2011 Aug 23;108(34):14234-9
pubmed: 21821793
Science. 2007 Dec 21;318(5858):1917-20
pubmed: 18029452
Stem Cell Res Ther. 2015 Mar 26;6:48
pubmed: 25889591
BMJ. 2007 Jan 27;334(7586):177
pubmed: 17255594

Auteurs

Qi Wang (Q)

Department of Molecular Medicine, Mayo Clinic College of Medicine, Rochester, MN, 55905, USA.

Alanna Vossen (A)

Department of Molecular Medicine, Mayo Clinic College of Medicine, Rochester, MN, 55905, USA.

Yasuhiro Ikeda (Y)

Department of Molecular Medicine, Mayo Clinic College of Medicine, Rochester, MN, 55905, USA.
Virology and Gene Therapy Graduate Track, Mayo Clinic College of Medicine, Rochester, MN, 55905, USA.

Patricia Devaux (P)

Department of Molecular Medicine, Mayo Clinic College of Medicine, Rochester, MN, 55905, USA. devaux.patricia@mayo.edu.
Virology and Gene Therapy Graduate Track, Mayo Clinic College of Medicine, Rochester, MN, 55905, USA. devaux.patricia@mayo.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH